[Translation] A single-dose, randomized, open-label, two-period, two-sequence, crossover bioequivalence study of diacerein capsules in healthy volunteers under fasting and fed conditions

主要研究目的:研究空腹和餐后状态下单次口服受试制剂双醋瑞因胶囊（规格：50mg，生产持证单位：葵花药业集团湖北武当有限公司）与参比制剂双醋瑞因胶囊（商品名：安必丁®ARTRODAR®，规格：50mg，生产持证单位：TRB Pharma S.A.）在中国健康人体的相对生物利用度，分析两种制剂的药代动力学参数，评估空腹和餐后状态口服两种制剂的生物等效性，为该药的申报及临床用药提供参考依据。次要研究目的:空腹和餐后状态下，研究单次口服双醋瑞因胶囊受试制剂和参比制剂在健康成年受试者中的安全性。

[Translation]

Main research objectives: To study the relative bioavailability of the test preparation Diacerein Capsules (specification: 50 mg, licensed manufacturer: Sunflower Pharmaceutical Group Hubei Wudang Co., Ltd.) and the reference preparation Diacerein Capsules (trade name: ARTRODAR®, specification: 50 mg, licensed manufacturer: TRB Pharma S.A.) in healthy Chinese subjects after a single oral administration in the fasting and fed state, analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state, and provide a reference for the application and clinical use of the drug. Secondary research objectives: To study the safety of the test preparation and reference preparation of Diacerein Capsules in healthy adult subjects after a single oral administration in the fasting and fed state.

Start Date27 Dec 2024

Sponsor / Collaborator

Hubei Wudang Jinding Pharmaceutical Co. Ltd.

CTR20244602

/ CompletedNot Applicable

双醋瑞因胶囊在中国健康受试者空腹和餐后状态下的单中心、随机、开放、两制剂、两周期、两序列、单次给药、双交叉生物等效性研究

[Translation] A single-center, randomized, open-label, two-formulation, two-period, two-sequence, single-dose, double-crossover bioequivalence study of diacerein capsules in Chinese healthy volunteers under fasting and fed conditions

主要目的：以大黄酸（双醋瑞因的活性代谢产物）的主要药代动力学参数（AUC和Cmax）为生物等效性的评价指标，在中国健康受试者空腹和餐后状态下评估受试制剂（杭州朱养心药业有限公司申报的双醋瑞因胶囊，规格：50mg）和参比制剂（TRB Pharma S.A持证的双醋瑞因胶囊，规格：50mg；商品名：安必丁®ARTRODAR®）的生物等效性。次要目的：观察空腹和餐后状态下受试制剂和参比制剂的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of the test preparation (Diacerein Capsules declared by Hangzhou Zhuyangxin Pharmaceutical Co., Ltd., specification: 50 mg) and the reference preparation (Diacerein Capsules certified by TRB Pharma S.A., specification: 50 mg; trade name: ARTRODAR®) in Chinese healthy subjects under fasting and fed conditions, using the main pharmacokinetic parameters (AUC and Cmax) of rhein (active metabolite of diacerein) as bioequivalence evaluation indicators. Secondary objective: To observe the safety of the test preparation and the reference preparation under fasting and fed conditions.

Start Date04 Dec 2024

Sponsor / Collaborator

Hangzhou Zhuyangxin Pharmaceutical Co. Ltd.

CTR20244033

/ CompletedNot Applicable

双醋瑞因胶囊在中国成年健康受试者中的一项单中心、随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性研究

[Translation] A single-center, randomized, open-label, single-dose, fasting and fed, two-formulation, two-sequence, two-period crossover bioequivalence study of diacerein capsules in healthy Chinese adult subjects

主要研究目的考察单次单剂量口服（空腹/餐后）受试制剂双醋瑞因胶囊（规格：50mg，北京阳光诺和药物研究股份有限公司委托安徽佳和药业有限公司生产）与参比制剂双醋瑞因胶囊（商品名：安必丁®，规格：50mg，TRB Pharma S.A.生产），在中国健康人体的相对生物利用度，分析两种制剂的药代动力学参数，评价两制剂的生物等效性，为受试制剂双醋瑞因胶囊的申报及临床用药提供参考依据。次要研究目的评价空腹、餐后单次口服受试制剂和参比制剂在中国成年健康受试者中的安全性。

[Translation]

Main study objectives To investigate the relative bioavailability of the single-dose oral (fasting/postprandial) test preparation Diacerein Capsules (specification: 50mg, produced by Anhui Jiahe Pharmaceutical Co., Ltd. commissioned by Beijing Sunshine Novo Pharmaceutical Research Co., Ltd.) and the reference preparation Diacerein Capsules (trade name: Ambidine®, specification: 50mg, produced by TRB Pharma S.A.) in healthy Chinese subjects, analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence of the two preparations, and provide a reference for the application and clinical use of the test preparation Diacerein Capsules. Secondary study objectives To evaluate the safety of the test preparation and the reference preparation in Chinese healthy adult subjects after single oral administration on an empty stomach or after a meal.

Start Date25 Nov 2024

Sponsor / Collaborator

Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

100 Clinical Results associated with Diacerein

100 Translational Medicine associated with Diacerein

100 Patents (Medical) associated with Diacerein

795

Literatures (Medical) associated with Diacerein

01 Mar 2025·The Journal of Dermatology

Repurposing diacerein for the treatment of chronic wounds in recessive‐dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase‐9 expression

Article

Author: Wally, Verena ; Gruner, Stefanie ; Ablinger, Michael ; Diem, Anja ; Bauer, Johann W. ; Gratz, Iris K. ; Wimmer, Monika ; Laimer, Martin ; Dorfer, Sonja ; Zauner, Roland ; Guttmann‐Gruber, Christina ; Hummel, Julia I. ; Hofbauer, Josefina Piñón ; Koller, Ulrich ; Ibrahimpašić, Selma

AbstractRecessive dystrophic epidermolysis bullosa (RDEB) is caused by mutations in COL7A1, leading to loss or dysfunction of type‐VII collagen (C7), a protein essential for skin stability. Clinically, patients suffer from severe skin blistering, chronic or recurrent wounds, and scarring, which predispose to early onset of aggressive squamous cell carcinoma. Previous studies showed that RDEB‐keratinocytes (RDEB‐KC) express high levels of matrix‐metalloproteinase 9 (MMP‐9), a molecule known to play a crucial role in wound chronification if dysregulated. We investigated the potential of diacerein, a small molecule that interferes with the MMP‐9 regulatory pathway, to improve wound healing in a 5‐year old RDEB patient presenting with chronic, generalized skin involvement unresponsive to previous treatment approaches. Upon 4 weeks of topical therapy applied to the patient's back, parents reported a nearly complete wound closure and a significant increase in quality of life. We also provide evidence that diacerein treatment of patient keratinocytes results in a downregulation of MMP‐9 expression, accompanied by a reduction in their ability to degrade a fibrinogen matrix. These data characterize diacerein as a potential candidate for improving wound healing in RDEB through its impact on inflammatory as well as epithelial cells.

02 Jan 2025·Journal of Liposome Research

Transdermal application of diacerin loaded-terpene enriched invasomes: an approach to augment anti-edema and nociception inhibition activity

Article

Author: Aziz, Diana E. ; Sadek, Mohamed A. ; Ahmed, Sadek ; Farag, Michael M.

This study aimed to formulate diacerein loaded terpene-enriched invasomes (DCN-TINV) to fulfill a fruitful management of osteoarthritis. A 2³ factorial design was adopted, including A: cholesterol concentration (%w/v), B: ethanol volume (mL) and C: phosphatidylcholine: drug ratio as the studied factors. Invasomes were constructed using the thin film hydration technique. Herein, percent entrapment efficiency (EE%), particle size (PS), poly-dispersity index (PDI) and zeta potential (ZP) were statistically analyzed using Design-Expert^® software to select the optimum formula. The selected criteria for detecting the optimum formula were restricting PS (<350 nm), dismissing PDI, magnifying ZP (as absolute value) and EE%. The selected formula was further scrutinized through multiple in-vitro studies, including Fourier-transform infrared spectroscopy, differential scanning calorimetry, pH measurement, stability study, release profile and transmission electron microscopy. Furthermore, the ex-vivo performance was evaluated through ex-vivo skin permeation and deposition. Finally, it was subjected to an array of in-vivo tests, namely Draize test, histopathology, In-vivo skin penetration, edema size, and nociception inhibition measurements. The optimum formula with desirability (0.913) demonstrated EE% (89.21% ± 2.12%), PS (319.75 ± 10.11 nm), ZP (-55 ± 3.96 mV) and a prolonged release profile. Intriguingly, revamped skin permeation (1143 ± 32.11 µg/cm²), nociception inhibition (77%) and In-vivo skin penetration (144 µm) compared to DCN suspension (285 ± 21.25 µg/cm², 26% and 48 µm, respectively) were displayed. The optimum DCN-TINV exhibited plausible safety and stability profiles consolidated with auspicious efficacy for better management of osteoarthritis.

01 Jan 2025·Journal of Pharmaceutical and Biomedical Analysis

Integrated metabolomics and network pharmacology to explore the clinical efficacy and mechanism of Yinchenhao decoction combined with nucleoside analogues on chronic hepatitis B

Article

Author: Su, Shibing ; Jiang, Yulang ; Cao, Hongyan ; Liu, Lu ; Xie, Dong ; Huang, Yanping ; Wang, Zheng ; Sun, Mingyu ; Zhang, Qin ; Song, Jingru ; Zhou, Mingmei ; Hui, Dengcheng ; Dai, Yancheng ; Ye, Guan

Yinchenhao decoction (YCHD) is widely used in the treatment of damp-heat syndrome of chronic hepatitis B (CHB), but it remains unclear about the active compounds in YCHD and its potential mechanism for treating CHB. The purpose of this work is to evaluate the clinical efficacy of YCHD combined with nucleoside analogues (NAs) for the treatment of CHB. Besides, based on the exact clinical efficacy, we combined serum metabolomics and network pharmacology to screen differential metabolites and related pathways regulated by YCHD to investigate the possible mechanism for treating CHB. It revealed that NAs plus YCHD could significantly improve alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, increase HBV-DNA negative rate (P<0.05), reduce the levels of inflammatory factors and LSM (both P<0.05), regulate lipids (P<0.05), and improve the symptoms of traditional Chinese medicine (TCM) (P<0.05) in CHB patients. YCHD was relatively safe. It showed 30 active compounds including chlorogenic acid, geniposide, emodin, quercetin, kaempferol, β-sitosterol and aloe emodin, and 115 key targets which were related to the regulation of lipids and reduction of oxidative stress related to the effect of YCHD in CHB in the network pharmacology analysis. We found 9 core targets and 4 key metabolites according to metabolomics, which were partly consistent with the network pharmacology findings. It proved that network pharmacology combined with metabolomics can well explain the "multi-component-multi-target" mechanism of complex TCM.

News (Medical) associated with Diacerein

14 Mar 2025

·www.prnewswire.com

Accropeutics Secured $12 Million in Series B Plus Financing

Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST). Cash runway extended into the second half of 2026 NEW YORK and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the closing of its $12 million Series B Plus financing. The round was led by Shenzhen Capital Group (SCGC), an existing investor, with participation from Morningside Ventures, also an existing investor, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST). The proceeds from the Series B Plus financing will be used to generate more clinical data for AC-101, a RIPK2 inhibitor, in an ongoing Phase Ib clinical trial for patients with Ulcerative Colitis (UC). Accropeutics' other clinical-stage assets include AC-201, a selective TYK2/JAK1 inhibitor, currently in an ongoing Phase II trial for patients with moderate-to-severe Psoriasis, and for multiple additional indications; and AC-003, a RIPK1 inhibitor, currently in an ongoing Phase Ib trial for patients with acute Graft-versus-Host Disease (aGvHD). The company also has multiple I&I assets in the pre-clinical stage. Dr. Xiaohu (Jason) Zhang, Co-founder and CEO of Accropeutics, stated: " With this round of financing, we are able to continue advancing our lead programs and solidify our position as an innovative, multi-program, clinical-stage biotech company. I am grateful to our existing and new investors, who share our vision that we can transform the treatment landscape for a wide range of I&I diseases with potentially best-in-class therapies. " About Accropeutics Accropeutics Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for immune mediated inflammatory disease, by targeting molecular mechanisms of regulated cell death. The company has a robust portfolio of innovative compounds in various stages of development, ranging from lead optimization to clinical testing. AC-101, a selective RIPK2 inhibitor, has completed Phase I clinical trials in Australia and China, and is currently undergoing a Phase Ib trial for Ulcerative Colitis (UC). AC-201, a selective TYK2/JAK1 inhibitor, has completed Phase I study in Australia and China, and is currently undergoing a Phase II trial for Psoriasis in China. AC-003, a selective RIPK1 inhibitor, has completed Phase I clinical trials in China and the United States as of August 2023, and is currently undergoing a Phase Ib clinical trial in aGVHD. Accropeutics' pipeline also includes several assets in the research and pre-clinical stages of development. Accropeutics owns global rights for all of its assets, and boasts 23 issued patents in China, Japan, Korea, US and the EU. For more information, visit Contacts Kenneth Gao SVP, Corporate Development & Strategy [email protected] SOURCE Accropeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1Phase 2

13 Feb 2025

·pipelinereview.com

Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101

NEW YORK, NY, USA I February 13, 2025 I Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the dosing of their first patient in the Phase Ib clinical trial of AC-101. AC-101 is a novel RIPK2 inhibitor being developed for the treatment of moderate-to-severe Ulcerative Colitis (UC). This multi-center, open-label clinical trial will evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of AC-101 in Chinese patients with moderate-to-severe UC. Accropeutics recently secured U.S. FDA IND clearance for AC-101 to enable its planned Phase 2 Multi-Regional Clinical Trial (MRCT) for this indication. Dr. Xiaohu Zhang, co-founder and CEO of Accropeutics said, “Dosing of the first patient in AC-101’s Phase 1b study represents a significant step towards advancing this novel oral therapeutic for treatment of patients suffering from Ulcerative Colitis. We believe that RIPK2 comprises a critical target in the pathogenesis of inflammatory bowel disease, including Ulcerative Colitis and Crohn’s Disease, and that targeting it with AC-101 will provide a novel front-line option to patients in urgent need of efficacious, non-immunosuppressive treatments.” About Ulcerative Colitis (UC) Ulcerative Colitis (UC), is a chronic, immune-mediated, inflammatory disease of the digestive tract, characterized by the inflammation of the large intestine and an intermittent relapsing–remitting disease course. Recurring UC flares lead to significant cumulative morbidity and long-standing disease is associated with significant risk of developing colorectal cancer. Patients with active disease are more likely to experience psychological comorbidity, including stress, anxiety and depression, that significantly impair their quality of life and work productivity. While many advanced therapeutics exist to manage moderate-to-severe UC, the majority of these drugs associate with less than impressive clinical remission rates (20–30%), along with a high incidence of secondary loss of response in patients who initially responded. About RIPK2 Receptor interacting protein kinase 2 (RIP2 or RIPK2) is a member of the receptor interacting serine/threonine protein kinase family. NOD/RIPK2 dependent signaling pathway dysregulation is implicated in several forms of immune mediated inflammatory disease, including inflammatory bowel disease (IBD) and sarcoidosis. About AC-101 AC-101 was developed from the company’s “regulatory cell death and inflammation” drug discovery platform. Preclinical studies show that AC-101 effectively inhibits the release of the NOD-RIPK2 dependent inflammatory factors and significantly protects tissue damage in nonclinical in-vivo models. AC-101 has completed Phase I clinical testing in Australia and China with evidence of strong safety and PK/PD signal. About Accropeutics Accropeutics Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for immune mediated inflammatory disease, by targeting molecular mechanisms of regulated cell death. The company has a robust portfolio of innovative compounds in various stages of development, ranging from lead optimization to clinical testing. AC-003, a selective RIPK1 inhibitor, completed phase I clinical testing in China and the United States, and is undergoing phase Ib clinical trials in aGVHD. AC-201, a selective TYK2/JAK1 inhibitor, has completed Phase I testing in Australia and China, and is currently undergoing a Phase II psoriasis trial in China. The Accropeutics portfolio additionally includes several assets in research and preclinical stages of development. Accropeutics entirely owns global rights for all of its assets, and boasts 23 issued patents in China, Japan, Korea, US and the EU. SOURCE: Accropeutics

Phase 1Phase 2IND

13 Feb 2025

·www.prnewswire.com

Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the dosing of their first patient in the Phase Ib clinical trial of AC-101. AC-101 is a novel RIPK2 inhibitor being developed for the treatment of moderate-to-severe Ulcerative Colitis (UC). This multi-center, open-label clinical trial will evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of AC-101 in Chinese patients with moderate-to-severe UC. Accropeutics recently secured U.S. FDA IND clearance for AC-101 to enable its planned Phase 2 Multi-Regional Clinical Trial (MRCT) for this indication. Dr. Xiaohu Zhang, co-founder and CEO of Accropeutics said, "Dosing of the first patient in AC-101's Phase 1b study represents a significant step towards advancing this novel oral therapeutic for treatment of patients suffering from Ulcerative Colitis. We believe that RIPK2 comprises a critical target in the pathogenesis of inflammatory bowel disease, including Ulcerative Colitis and Crohn's Disease, and that targeting it with AC-101 will provide a novel front-line option to patients in urgent need of efficacious, non-immunosuppressive treatments." About Ulcerative Colitis (UC) Ulcerative Colitis (UC), is a chronic, immune-mediated, inflammatory disease of the digestive tract, characterized by the inflammation of the large intestine and an intermittent relapsing–remitting disease course. Recurring UC flares lead to significant cumulative morbidity and long-standing disease is associated with significant risk of developing colorectal cancer. Patients with active disease are more likely to experience psychological comorbidity, including stress, anxiety and depression, that significantly impair their quality of life and work productivity. While many advanced therapeutics exist to manage moderate-to-severe UC, the majority of these drugs associate with less than impressive clinical remission rates (20–30%), along with a high incidence of secondary loss of response in patients who initially responded. About RIPK2 Receptor interacting protein kinase 2 (RIP2 or RIPK2) is a member of the receptor interacting serine/threonine protein kinase family. NOD/RIPK2 dependent signaling pathway dysregulation is implicated in several forms of immune mediated inflammatory disease, including inflammatory bowel disease (IBD) and sarcoidosis. About AC-101 AC-101 was developed from the company's "regulatory cell death and inflammation" drug discovery platform. Preclinical studies show that AC-101 effectively inhibits the release of the NOD-RIPK2 dependent inflammatory factors and significantly protects tissue damage in nonclinical in-vivo models. AC-101 has completed Phase I clinical testing in Australia and China with evidence of strong safety and PK/PD signal. About Accropeutics Accropeutics Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for immune mediated inflammatory disease, by targeting molecular mechanisms of regulated cell death. The company has a robust portfolio of innovative compounds in various stages of development, ranging from lead optimization to clinical testing. AC-003, a selective RIPK1 inhibitor, completed phase I clinical testing in China and the United States, and is undergoing phase Ib clinical trials in aGVHD. AC-201, a selective TYK2/JAK1 inhibitor, has completed Phase I testing in Australia and China, and is currently undergoing a Phase II psoriasis trial in China. The Accropeutics portfolio additionally includes several assets in research and preclinical stages of development. Accropeutics entirely owns global rights for all of its assets, and boasts 23 issued patents in China, Japan, Korea, US and the EU. Contact: Accropeutics Kenneth Gao Senior Vice President [email protected] SOURCE Accropeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1INDPhase 2

100 Deals associated with Diacerein

External Link

KEGG	Wiki	ATC	Drug Bank
D07270	Diacerein	M01AX21	DB11994

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arthritis	Italy	Proter Srl	01 Dec 1986
Osteoarthritis	China	Trb Pharma Sa	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epidermolysis Bullosa Simplex	Phase 3	Philippines	TWi Biotechnology, Inc.	04 Apr 2024
Epidermolysis Bullosa Simplex	Phase 3	United States	TWi Biotechnology, Inc.	04 Apr 2024
Epidermolysis Bullosa Simplex	Phase 3	Australia	TWi Biotechnology, Inc.	04 Apr 2024
Epidermolysis Bullosa Simplex	Phase 3	Austria	TWi Biotechnology, Inc.	04 Apr 2024
Epidermolysis Bullosa Simplex	Phase 3	United Kingdom	TWi Biotechnology, Inc.	04 Apr 2024
Epidermolysis Bullosa Simplex	Phase 3	Italy	TWi Biotechnology, Inc.	04 Apr 2024
Epidermolysis Bullosa Simplex	Phase 3	Poland	TWi Biotechnology, Inc.	04 Apr 2024
Epidermolysis Bullosa Simplex	Phase 3	Taiwan Province	TWi Biotechnology, Inc.	04 Apr 2024
Epidermolysis Bullosa Simplex	Phase 3	Israel	TWi Biotechnology, Inc.	04 Apr 2024
Epidermolysis Bullosa Simplex	Phase 3	Belgium	TWi Biotechnology, Inc.	04 Apr 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04917679 (Pubmed \| Blood) Manual	Phase 2	Purpura, Thrombocytopenic, Idiopathic	102	Eltrombopag plus diacerein	(qwzmmvyvms) = tldqljwzlk lyvpvdbiqw (flhttbargd ) View more	Positive	03 Jul 2024
				Eltrombopag	(qwzmmvyvms) = hapezgebdl lyvpvdbiqw (flhttbargd ) View more
NCT02688400 (DISSCO, CTgov)	Phase 3	Osteoarthritis, Knee	380	Placebo+Diacerein (Diacerein)	ytyfqaarga(pyzmondgqs) = cjqcjmtabc nfkmguiumq (vqikwzwnjj, xllbvymhof - xhodzwxvcv) View more	-	01 Dec 2023
				Placebo+Celecoxib (Celecoxib)	ytyfqaarga(pyzmondgqs) = hbdqhdlkvt nfkmguiumq (vqikwzwnjj, yfqrrkesgj - kmfkrebyyu) View more
ASCO_GU2023	Not Applicable	Metastatic castration-resistant prostate cancer	153	androgen receptor targeted (ART) therapies (Patients <75 years old)	(zxdlaweybx) = ddmjdopvbz dudvxmsdkg (hfsgeipokv ) View more	-	21 Feb 2023
				androgen receptor targeted (ART) therapies (Patients ≥75 years old)	(zxdlaweybx) = swdyrniaqg dudvxmsdkg (hfsgeipokv ) View more
NCT04917679 (ASH 12022 \| ASH 22022) Manual	Phase 2	Purpura, Thrombocytopenic, Idiopathic	66	Eltrombopag 75 mg+Diacerein 50 mg	ilfyeewuod(tqfqawqtic) = spgffqxqxi gdqotdblqv (yymaiqgmze ) View more	Positive	15 Nov 2022
				Eltrombopag 75 mg	ilfyeewuod(tqfqawqtic) = fioeshflhx gdqotdblqv (yymaiqgmze ) View more
WCO_IOF_ESCEO2021	Not Applicable	-	61	Diacerein 50 mg twice daily	qiklycbsdm(tcmhhxfjju) = 34% hfjjwpgalb (trnffgfodo ) View more	Positive	26 Aug 2021
NCT03060447 (CTgov)	Phase 1	HIV Infections	25	Placebo+ART (Placebo)	(vktvghklbo) = xpdwmnsyge zdbcfsygbs (lfhdtzbbpg, jfiuotncpb - nhtvssxsew) View more	-	21 Apr 2021
				ART+Vesatolimod (Vesatolimod)	thtogrzbxv(cohgppjecm) = nwlcwihzrw wratlacjpz (fpotvywtnn, ytcuuvdmtp - tgzfbzepbw) View more
IAS2021	Not Applicable	-	-	ART (Fiebig I-II)	ldnlsjgnbk(oxfuferzsm) = aqcnxyxcda aubwxetkry (nrhlbqzgrs ) View more	-	01 Jan 2021
				ART (Fiebig III-IV)	ldnlsjgnbk(oxfuferzsm) = jzssreympc aubwxetkry (nrhlbqzgrs ) View more
NCT02688400 (DISSCO, Pubmed \| Rheumatology (Oxford)) Manual	Phase 3	Osteoarthritis, Knee	380	diacerein	(qvsnrhlcks) = lwdkfemngy uorfxqbbrr (oujpadsqhx, 0.9) View more	Non-inferior	01 Dec 2020
				celecoxib	(qvsnrhlcks) = enmpwupmrs uorfxqbbrr (oujpadsqhx, 0.9) View more
NCT02287818 (CTgov)	Phase 2	Gout	127	Placebo+Febuxostat (Placebo)	nlwtziyxuw(elibzbuifn) = ilmshulbgp azqdvmbifg (wergezvtlx, raykgsuxrv - fbebsepvyz) View more	-	28 Oct 2020
				AC-201+Febuxostat (AC-201)	nlwtziyxuw(elibzbuifn) = iftxmgaezj azqdvmbifg (wergezvtlx, oavcrqswcb - zljzwioqhq) View more
NCT03389308 (CTgov)	Phase 2	Epidermolysis Bullosa Simplex	51	Diacerein	(ilhbdyfysm) = qgdljofkke imidgpklqo (mqwypmwwwa, mzrlnpferv - pvtjxdwoyn) View more	-	16 Sep 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis